title: Response to Jani et al. A prospective, randomized, doubleblind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
authors.affiliation: Rheumatology Department, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
authors.forename: Barry
authors.initials: B
authors.lastname: Kane
mesh_terms: D000068879:Adalimumab; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid; D059451:Biosimilar Pharmaceuticals; D004311:Double-Blind Method; D006801:Humans; D011446:Prospective Studies
chemical_list: D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D000068879:Adalimumab